Philip Comp to Prospective Studies
This is a "connection" page, showing publications Philip Comp has written about Prospective Studies.
Connection Strength
0.173
-
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001 Mar; 83(3):336-45.
Score: 0.036
-
An association between plasma free protein s concentration and risk of coronary heart disease in middle-aged men. Thromb Res. 2001 Jan 15; 101(2):1-11.
Score: 0.035
-
Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care. The Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Am J Cardiol. 1996 Nov 01; 78(9):1074-6.
Score: 0.026
-
Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. Thromb Res. 2015 Dec; 136(6):1120-5.
Score: 0.025
-
Effect of treatment with low-dose warfarin-aspirin on activated factor VII. Blood. 1995 Jun 01; 85(11):3034-9.
Score: 0.024
-
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005 Oct; 87(10):2169-77.
Score: 0.012
-
Predictive value of compression ultrasonography for deep vein thrombosis in symptomatic outpatients: clinical implications of the site of vein noncompressibility. Arch Intern Med. 2000 Feb 14; 160(3):309-13.
Score: 0.008
-
The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998 Jan 01; 128(1):1-7.
Score: 0.007